drugset / Trial / NCT06034821
Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan
Phase 4
Enrolling by invitation
1500 enrolled
Brigham and Women's Hospital
Icahn School of Medicine at Mount Sinai · collabJohns Hopkins University · collabMassachusetts General Hospital · collabMclean Hospital · collabThe Cleveland Clinic · collabThe University of Texas Health Science Center, Houston · collabUC San Francisco · collabUT Health · collabUniversity of Pittsburgh · collabUniversity of Toronto · collabUniversity of Utah · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a randomized open-label single-blind non-inferiority comparative effectiveness study of ECT vs. KET for the treatment of Acute Suicidal Depression (ASD).
Timeline
- Start
- 2023-10-01
- Primary completion
- 2030-10-01
- Completion
- 2030-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ketamine | Small molecule | 0.5 mg/kg | Intravenous |